Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8383659	TARSUS	Isoxazoline derivatives as pesticides	Jan, 2030 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690827	TARSUS	Methods for treating ocular Demodex using lotilaner formulations	Dec, 2038 (14 years from now)
US11690826	TARSUS	Methods for treating demodex blepharitis using lotilaner formulations	Dec, 2038 (14 years from now)
US11197847	TARSUS	Isoxazoline parasiticide formulations and methods for treating blepharitis	Dec, 2038 (14 years from now)
US10835517	TARSUS	Methods for treating ocular demodex using isoxazoline parasiticide formulations	Dec, 2038 (14 years from now)
US11752137	TARSUS	Ophthalmic compositions for treating ocular Demodex using lotilaner formulations	Dec, 2038 (14 years from now)

Xdemvy is owned by Tarsus.

Xdemvy contains Lotilaner.

Xdemvy has a total of 6 drug patents out of which 0 drug patents have expired.

Xdemvy was authorised for market use on 24 July, 2023.

Xdemvy is available in solution/drops;ophthalmic dosage forms.

Xdemvy can be used as treatment of demodex blepharitis via topical administration to an ocular surface.

Drug patent challenges can be filed against Xdemvy from 25 July, 2027.

The generics of Xdemvy are possible to be released after 14 December, 2038.

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 24, 2028

NCE-1 date: 25 July, 2027

Market Authorisation Date: 24 July, 2023

Treatment: Treatment of demodex blepharitis via topical administration to an ocular surface

Dosage: SOLUTION/DROPS;OPHTHALMIC

Xdemvy patents expiration